Compounds that acts through the release of reactive oxygen and nitrogen species, such as furoxan and nitro compounds, have been extensively explored as antituberculosis agents . Brönstrup and coworkers have reported a series of nitrofuran derivatives with selective activity against Mtb. Specifically, compound (23) (Figure 9) exhibited MIC90 of 11 μM against two MDR-TB clinical isolates. The authors also evaluated the spectrum of activity for compound (23) and they did not find activity against a panel of Gram-positive and Gram-negative bacteria . The nitroimidazole class is another important scaffold in the medical chemistry of antituberculosis agents, especially its main representative, the drug delamanid (Deltyba®, Otsuka Pharmaceutical) . A series of nitroimidazole derivatives have been reported as presenting an outstanding antituberculosis activity against an MDR-TB clinical isolate. For instance, the most promising compound (24) (Figure 9) presented a MIC90 of 0.11 μM. The in vivo pharmacokinetics showed a good profile, with Cmax of 0.54 μg/mL, T1/2 of 2 h and no CYP inhibition at three different concentrations tested (10, 30 and 100 μM). In vivo efficacy of compound (24) was assessed using a mice model for acute infection. Using an infected mice model, this compound was able to reduce the bacterial burden on a logarithmic scale of 1.8 log10 CFU at 100 mg kg−1 once daily for 28 days. . Furoxan derivatives also have been reported showing its promising application as antitubercular compounds. Specifically, compound (25) (Figure 9) exhibited MIC90 of 7 μM against MDR-TB clinical isolates. Furthermore, the authors have demonstrated that this compound may act through the release of nitric oxide . Smith and coworkers have discovered a nitrotriazole derivative as a promising antitubercular agent. Compound (26) (Figure 9) showed MIC90 values below 3.9 μM against several single drug-resistant strains. In addition, compound (26) exhibited intracellular activity against infected J774 macrophages, resulting in a reduction of 1.18 log of intracellular bacilli burden .